SYBX Synlogic, Inc.: Rasio rega marang prakiraan pendapatan

Synlogic - logo grafis emiten SYBX

Synlogic, Inc. (SYBX) is vulnerable to disruptions in global laboratory equipment supplies. The team maintains its position through the uniqueness of its "living" medicines platform, while the financial strategy relies on cost optimization and licensing. The forward price-to-sales ratio helps assess the business's market value relative to expected sales, with the latest reading standing at 1313.80.

Synlogic Inc. - Rasio kapitalisasi marang dodolan sing dikarepake SYBX (periode 04.07.2022 - 10.05.2025)

Ringkesan rincian data analitis synlogictx.com (SYBX)

- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
Analisis komprehensif perusahaan:Synlogic Corp (SYBX)
Produk asli Synlogic

The forward P/S reflects the market value of Synlogic, Inc. (SYBX) relative to its expected annual revenue, allowing for an assessment of the premium paid for future cash flow. By analyzing the forward P/S trend, an investor determines whether the capitalization is appropriate amidst the restructuring of Synlogic, Inc. (SYBX), where supply chain optimization and the change of laboratory partners directly impact the potential for preserving scientific assets.

Analisis pesaing

Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NewAmsterdam Pharma N.V. (NAMS)|Multiplikator forward rega marang pendapatan Soleno Therapeutics Corp SLNO|Rasio rega marang prakiraan pendapatan Amicus Therapeutics FOLD|Rasio kapitalisasi marang dodolan sing dikarepake 89bio.com (ETNB)|AGIO: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Structure Therapeutics Inc|MiMedx Group (MDXG) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan RZLT|Rasio rega marang prakiraan pendapatan Lexicon Pharmaceuticals|Rasio rega marang prakiraan pendapatan MBX|Rasio rega marang prakiraan pendapatan Altimmune (ALT)|AARD - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S SGMT (Sagimet)|Prakiraan rega marang pendapatan BioAge Labs, Inc|Biomea Fusion, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Quince Therapeutics QNCX|GUTS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan vTv Therapeutics|Multiplikator forward rega marang pendapatan ATPC|PLUR: Rega forward marang dodolan|Multiplikator Forward P/S LPCN|Rasio kapitalisasi marang dodolan sing dikarepake matinasbiopharma.com|Rasio rega marang prakiraan pendapatan Spruce Biosciences, Inc. SPRB|GLTO: Kapitalisasi marang prakiraan pendapatan|Carmell Corp - Multiplikator Forward P/S|Lumos Therapeutics (LUMO) - Multiplikator forward rega marang pendapatan|ONVO (Organovo Holdings, Inc.) - Multiplikator forward rega marang pendapatan|RDUS - Rasio kapitalisasi marang dodolan sing dikarepake